MedTrace Logo

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

NCT00374140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-10-19

Study results available
· View outcomes & findings →

Summary

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.

Conditions

Interventions

DRUG

RAD001 (everolimus)

10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities

Sponsors & Collaborators

Principal Investigators

  • Ahmad Tarhini, MD, PhD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-12-31
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00374140 on ClinicalTrials.gov